Conflict of interest statement: Financial disclosures: Matthew R. Smith 
certifies that all conflicts of interest, including specific financial interests 
and relationships and affiliations relevant to the subject matter or materials 
discussed in the manuscript (eg, employment/affiliation, grants or funding, 
consultancies, honoraria, stock ownership or options, expert testimony, 
royalties, or patents filed, received, or pending), are the following: Matthew 
R. Smith has served as a consultant to Janssen Research & Development. Emmanuel 
S. Antonarakis has served as a consultant/adviser to Janssen Biotech, Astellas, 
Medivation, ESSA, Sanofi, and Dendreon; he has received research funding from 
Aragon Pharmaceuticals, Johnson & Johnson, Janssen Biotech, Astellas, Tokai, 
Sanofi, Dendreon, Exelixis, Novartis, and Genentech. Charles J. Ryan has 
received honoraria from Janssen Research & Development. William R. Berry has 
received research grants from AHRQ. Neal D. Shore is a consultant/adviser to 
Algeta, Amgen, Bayer, BNI, Dendreon, Ferring, Janssen, Millennium, and Sanofi. 
Glenn Liu has nothing to report. Joshi J. Alumkal has received research funding 
from Aragon Pharmaceuticals. Celestia S. Higano received consulting fees or 
honoraria from AbbVie, Algeta, Astellas, Bayer, Dendreon, Genentech, Johnson & 
Johnson, Medivation, Novartis, Pfizer, and Veridex; grants or research support 
from Amgen, Aragon Pharmaceuticals, AstraZeneca, Bayer, Dendreon, Exelixis, 
Genentech, Johnson & Johnson, Medivation, Millennium, Novartis, OncoGenex, 
Sanofi-Aventis US, Taxynergy, and Teva; and other financial benefits from Cell 
Therapeutics. Edna Chow Maneval was an employee at Aragon Pharmaceuticals. 
Rajesh Bandekar is an employee of Janssen Research & Development and holds stock 
and stock options in Johnson & Johnson. Carla J. de Boer is an employee of 
Janssen Biologics and holds stock and stock options in Johnson & Johnson. 
Margaret K. Yu is an employee of Janssen Research & Development and holds stock 
and stock options in Johnson & Johnson. Dana E. Rathkopf has served as a 
consultant/adviser to and has received research funding from Janssen Research & 
Development, AstraZeneca, Celgene, Ferring, Medivation, Millennium/ Takeda, and 
Novartis.